Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 6:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 60 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Nicotine patch, nicotine inhaler, bupropion Clear all
Completed Phase 4 Interventional Results available

A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV

NCT04490057
View directory record Official record
Conditions
Tobacco Use Cessation
Interventions
Nicotine patch, nicotine gum, nicotine nasal spray, nicotine inhaler, Varenicline or bupropion, Contingency Management
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Bridgeport, Connecticut • New Haven, Connecticut • Brooklyn, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Smoking Relapse Prevention in Schizophrenia

NCT00320697
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder, Smokers
Interventions
bupropion + nicotine patch + nicotine gum or lozenges, Placebo pill + placebo patch
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 70 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional

Bupropion as an Adjunct to the Nicotine Patch Plus CBT

NCT00142831
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Pharmacotherapies for Smoking Cessation
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
20 Years to 65 Years
Enrollment
293 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Maintaining Abstinence in Chronic Cigarette Smokers - 1

NCT00087880
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Bupropion and NRT
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years and older
Enrollment
407 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Results available

Behaviorally Enhanced Counseling on Nicotine Dependence (BEACON) Trial.

NCT00991081
View directory record Official record
Conditions
Smoking
Interventions
Counseling, Self-help guide, Pharmacotherapy, Genetic feedback, verbal, Genetic feedback, printed
Behavioral · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
3
States / cities
Menlo Park, California • Stanford, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 19, 2012 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Individualizing Pharmacotherapy for African American Smokers

NCT03897439
View directory record Official record
Conditions
Smoking Cessation
Interventions
Nicotine patch, Varenicline Tartrate, Bupropion
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
392 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2023 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Results available

Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms

NCT00332644
View directory record Official record
Conditions
Nicotine Dependence
Interventions
nicotine patch, nicotine lozenge, nicotine patch + nicotine lozenge, bupropion, bupropion + lozenge, placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
1,504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
Madison, Wisconsin • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 30, 2011 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Impact of Smoking Cessation on Sleep - 5

NCT00132821
View directory record Official record
Conditions
Tobacco Use Cessation, Sleep Disorders
Interventions
Bupropion, Transdermal Nicotine Patch, Placebo Bupropion, Placebo transdermal nicotine patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2009
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Not applicable Interventional Results available

Mobile Contingency Management for Marijuana and Tobacco Cessation

NCT02869451
View directory record Official record
Conditions
Cigarette Smoking, Marijuana Abuse
Interventions
bupropion, transdermal nicotine patch, Nicotine polacrilex, nicotine lozenge, counseling for marijuana and smoking cessation, mobile contingency management
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 70 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2020 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Patch and Bupropion to Reduce Smoking Rates in Younger, Low-Income, and Minority Individuals

NCT00308763
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Nicotine Patch, Sustained Release Bupropion
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years to 45 Years
Enrollment
594 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 1, 2026, 6:00 PM EDT
Terminated Phase 3 Interventional

S0002 - A Program to Quit Smoking With or Without Bupropion in Treating Patients With Stage I or II Non-Small Cell Lung Cancer Who Have Undergone Surgery

NCT00032084
View directory record Official record
Conditions
Lung Cancer
Interventions
smoking cessation intervention, bupropion hydrochloride, nicotine, psychosocial assessment and care
Behavioral · Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
175
States / cities
Anniston, Alabama • Mobile, Alabama • Phoenix, Arizona + 115 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study To Evaluate Cardiac Assessments Following Different Treatments Of Smoking Cessation Medications In Subjects With And Without Psychiatric Disorders.

NCT01574703
View directory record Official record
Conditions
Smoking Cessation
Interventions
placebo, varenicline tartrate, bupropion hydrochloride, Nicotine Replacement Therapy Patch
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
4,595 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
65
States / cities
Mobile, Alabama • Encino, California • Escondido, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2016 · Synced Oct 1, 2026, 6:00 PM EDT
Active, not recruiting Not applicable Interventional

The Precision CAD Trial

NCT04755413
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Medical/Behavioral therapy, Standard of Care, Registry
Other
Lead sponsor
Emory University
Other
Eligibility
21 Years to 90 Years
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
5
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Results available

Adaptive Pharmacotherapy for Smoking Cessation

NCT02501265
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline Standard Protocol, Nicotine Patch Standard Protocol, Varenicline Adaptive Protocol, Nicotine Adaptive Protocol
Behavioral · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Results available

Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking

NCT02995915
View directory record Official record
Conditions
Smoking Cessation, Alcohol Drinking
Interventions
Nicotine Replacement Therapy, Bupropion, Cognitive Behavioral Treatment, Mobile Contingency Management, Mobile Monitoring
Other · Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 1, 2026, 6:00 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Treating Smokeless Tobacco Use in Rural Veterans

NCT02994082
View directory record Official record
Conditions
Smokeless Tobacco, Nicotine Dependence
Interventions
Tailored behavioral intervention, Behavioral activation for elevated depressive symptoms, Post-cessation weight gain management, Alcohol use risk reduction, Nicotine replacement therapy - transdermal nicotine patch, Nicotine replacement therapy - nicotine lozenge, Nicotine replacement therapy - nicotine gum, Bupropion sustained release, Varenicline, Combination nicotine replacement therapy, Combination nicotine replacement therapy + bupropion, Tobacco quit line, Educational materials
Behavioral · Drug
Lead sponsor
Mark Vander Weg
Federal
Eligibility
18 Years to 99 Years
Enrollment
123 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 24, 2019 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Extended Treatment for Smoking Cessation

NCT01330043
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion, Nicotine patch, Varenicline
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 65 Years
Enrollment
223 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 1, 2026, 6:00 PM EDT
Not yet recruiting Phase 4 Interventional

Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial

NCT07835555
View directory record Official record
Conditions
Tobacco Use Disorder/Cigarette Smoking, HIV
Interventions
nicotine patch, nicotine gum, nicotine lozenge, varenicline, bupropion, Multi-target Contingency Management, Teamlet booster
Drug · Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
5
States / cities
Bridgeport, Connecticut • New Haven, Connecticut • Jersey City, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Not applicable Interventional Results available

Integrating Tobacco Treatment Into Cancer Care: A Randomized Controlled Comparative Effectiveness Trial

NCT01871506
View directory record Official record
Conditions
Smoking Cessation
Interventions
Standard Care (SC), Intensive Counseling (IC)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effects of Transdermal Nicotine on Smoking, Craving and Withdrawal in People With Schizophrenia

NCT00218218
View directory record Official record
Conditions
Schizophrenia and Disorders With Psychotic Features, Tobacco Use Disorder, Schizophrenia
Interventions
Transdermal Nicotine Patch, 21 mg transdermal nicotine, placebo patch
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2005
U.S. locations
2
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 3 Interventional Results available

Mechanistic Evaluations of Pre-Cessation Therapies for Smoking Cessation

NCT01406223
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Varenicline, Bupropion, Nicotine patches, Placebo varenicline, Placebo bupropion, Placebo patch
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 1, 2026, 6:00 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Tailored Smoking Cessation Treatment for LIVE FOR LIFE® Participants

NCT01560507
View directory record Official record
Conditions
Cigarette Smoking, Nicotine Dependence
Interventions
varenicline (Chantix), bupropion (Zyban), nicotine patches
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 24, 2014 · Synced Oct 1, 2026, 6:00 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke

NCT00307203
View directory record Official record
Conditions
Tobacco-Use Disorder, Schizophrenia, Psychotic Disorders
Interventions
bupropion SR, Cognitive Behavioral Group Therapy, nicotine replacement therapy
Drug · Behavioral
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2004
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Oct 1, 2026, 6:00 PM EDT
Terminated Early Phase 1 Interventional

Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy

NCT02582008
View directory record Official record
Conditions
Current Smoker, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
Interventions
Bupropion Hydrochloride, Laboratory Biomarker Analysis, Nicotine Replacement, Quality-of-Life Assessment, Questionnaire Administration, Varenicline
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 1, 2026, 6:00 PM EDT